Entering text into the input field will update the search result below

3 Things In Biotech You Should Learn Today: November 5, 2017

Nov. 05, 2017 9:00 AM ETADRO, IONS, SNY4 Comments
Zach Hartman profile picture
Zach Hartman


  • Ionis takes its swing in Europe.
  • Aduro attacks myeloma.
  • Sanofi marks another grave in the fight against IPF.

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

Ionis takes its swing in Europe

Company: Ionis Pharmaceuticals (IONS)

Therapy: Inotersen, an antisense oligonucleotide targeting the transthyretin (TTR) gene

Disease: TTR-related familial amyloidosis

News: IONS announced that it has submitted a marketing authorization application to the EMA, seeking approval for inotersen. This application is supported by results from the NEURO-TTR study, which demonstrated significant improvement for inotersen compared with placebo in a number of meaningful endpoints relating to function in patients with neuropathy related to familial amyloidosis. This application will be evaluated under the Accelerated Assessment Program.

Looking forward: That's one good way to build quickly on good news. Just yesterday we covered the strong data presented by IONS, and now this? Moreover, the company intimated that it would be submitting to the FDA very soon, as early as next week. So this is one potential way to get an advantage over patisiran, which appears to be more favorably tolerated at this time: get approved sooner? We'll see. It's possible that safety issues could sink this application, but we're talking about an unambiguously effective therapy in an area of critical unmet need for patients. So I like its chances of approval.

Aduro attacks myeloma

Company: Aduro Biotech (ADRO)

Therapy: BION-1301, an anti-APRIL monoclonal antibody

Disease: Multiple myeloma

News: ADRO announced in its press release for its third-quarter filing that the FDA has granted approval to move forward with clinical study of BION-1301, an anti-APRIL monoclonal antibody that has demonstrated encouraging preclinical efficacy in multiple myeloma. APRIL is a ligand for BCMA, which has grown in importance as a hot new therapeutic target in myeloma studies.

Looking forward: ADRO

This article was written by

Zach Hartman profile picture
I am a former PhD scientist-turned-writer focused on cancer education. My writings in Seeking Alpha have been devoted to helping people identify promising investment opportunities in cancer research through commentary of recent events. Readers can learn more about other aspects of cancer research by visiting my site Invest Against Cancer.I also collaborate with Avisol Capital Partners on their Marketplace service known as the Total Pharma Tracker (TPT). Some of my work will be available to TPT subscribers either exclusively, or in advance. If you are interested, please click the link above!

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.